SCHEMBL23934205

SCHEMBL23934205

CN1C(=O)c2c(NC(=O)c3ccccc3)ccc(NC(=O)c3ccccc3)c2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.53
HPGD P15428 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MMP14 P50281 1/20 0.52
KCNMA1 Q12791 1/20 0.50
MAPT P10636 4/20 0.49
CYP1A2 P05177 4/20 0.49
CYP2C9 P11712 4/20 0.49
CYP2C19 P33261 3/20 0.49
MDM4 O15151 1/20 0.49
TP53 P04637 1/20 0.49
HDAC3 O15379 1/20 0.49
MAPK1 P28482 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
ADORA3 P0DMS8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934265 0.80 POLB (0.50) POLBMEN1KMT2AMAPTTP53
SCHEMBL23934281 0.80 MEN1 (0.53) POLBHPGDMEN1KMT2AMAPT
SCHEMBL6419867 0.76 MEN1 (0.82) POLBHPGDMEN1KMT2AMMP14
SCHEMBL30544874 0.76 MEN1 (0.82) POLBHPGDMEN1KMT2AMMP14
SCHEMBL23934285 0.74 ACE2 (0.48) POLBHPGDMEN1KMT2AMMP14
SCHEMBL1110180 0.73 MDM4 (0.73) POLBHPGDMEN1KMT2AMAPT
SCHEMBL8428897 0.73 MEN1 (0.60) POLBHPGDMEN1KMT2AMMP14
SCHEMBL16317646 0.72 KCNMA1 (0.76) POLBHPGDMEN1KMT2AKCNMA1
SCHEMBL7264464 0.72 POLB (0.77) POLBHPGDMEN1KMT2AKCNMA1
SCHEMBL19509669 0.72 HDAC3 (0.66) POLBHPGDMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885HPGD 4094/4885MEN1 2490/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 POLB 3272/4885HPGD 4094/4885MEN1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.